Lurasidone HCl

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Male, Healthy Normal Subjects

Conditions

Male, Healthy Normal Subjects

Trial Timeline

Aug 1, 2008 → Aug 1, 2008

NCT ID

NCT01082276

About Lurasidone HCl

Lurasidone HCl is a phase 1 stage product being developed by Sumitomo Pharma for Male, Healthy Normal Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT01082276. Target conditions include Male, Healthy Normal Subjects.

What happened to similar drugs?

3 of 20 similar drugs in Male, Healthy Normal Subjects were approved

Approved (3) Terminated (0) Active (17)

🔄Gemcitabine + liposomal doxorubicinEli LillyPhase 3

✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved

🔄Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3

🔄Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3

🔄SHR6390 + placeboJiangsu Hengrui MedicinePhase 3

🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3

🔄Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + PlacebosAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04432688	Pre-clinical	Completed	Dec 1, 2020	Jun 18, 2023	Schizophrenia
NCT01143090	Phase 3	Completed	Aug 1, 2010	—	Schizophrenia
NCT01143077	Phase 3	Completed	Jun 1, 2010	May 1, 2011	Schizophrenia
NCT01074632	Phase 1	Completed	May 1, 2009	Sep 1, 2009	Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
NCT01082263	Phase 1	Completed	Oct 1, 2008	Nov 1, 2008	Schizophrenia Patients
NCT01074073	Phase 1	Completed	Aug 1, 2008	Oct 1, 2008	Schizophrenia
NCT01082276	Phase 1	Completed	Aug 1, 2008	Aug 1, 2008	Male, Healthy Normal Subjects
NCT01082250	Phase 1	Completed	Jul 1, 2008	Sep 1, 2008	Schizophrenia
NCT00549718	Phase 3	Completed	Oct 1, 2007	Oct 1, 2010	Schizophrenia

Competing Products

20 competing products in Male, Healthy Normal Subjects

See all competitors

Product	Company	Stage	Hype Score
Fulvestrant	Dr. Reddy's Laboratories	Pre-clinical	19
ENZ215 + EU Sourced Prolia + US Sourced Prolia	Alkem Laboratories	Phase 1	29
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	39
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	40
[14C]-LY3549492 + LY3549492 + [14C]-LY3549492	Eli Lilly	Phase 1	29
CT-P41 + EU-approved Prolia	Celltrion	Phase 1	29
CT-P55 + US-licensed Cosentyx + EU-approved Cosentyx	Celltrion	Phase 1	29
CT-P52	Celltrion	Phase 1	36
CT-P43 + CT-P43	Celltrion	Phase 1	29
Telmisartan + Amlodipine + Rosuvastatin	Yuhan	Phase 1	29
ASP3325 + Placebo	Astellas Pharma	Phase 1	29
TRK-100STP	Astellas Pharma	Phase 1	29
Ensitrelvir	Shionogi	Phase 1	29
E6011 + E6011 Matching Placebo	Eisai	Phase 1	29
E6130 + Placebo	Eisai	Phase 1	29
Eribulin Injection [Halaven] + Paclitaxel injection	Eisai	Approved	39
E3112	Eisai	Phase 1	29
E2022 Tape Formulation	Eisai	Phase 1	29
Placebo + E3112	Eisai	Phase 1	29
[14C]-E6007	Eisai	Phase 1	29